15 billion cataract treatment market urgently needs to get rid of import dependence

Recently, since an article from the media so that Sapphire Eye drops into efficacy and publicity questioned the swirl, the paper directed at Sappus Eye drops brainwashing marketing, saying it Delay cataract patient treatment.

According to the American Academy of Ophthalmology's 2016 Clinical Guide to Adult Cataract, no drug has been found to effectively cure or delay the progression of cataracts.At present, the consensus among ophthalmologists in treating cataract is surgically treated. China's prevention of blindness blind website shows that no matter what kind of cataract, surgical treatment is the most effective means.

Cataracts are one of the most common causes of blindness, the main symptom of which is cataract, which is associated with the degree and location of lens opacity .Cataract has long been one of the leading causes of blindness. At present, China has the largest group of cataract patients in the world, about 60 million people, accounting for one-third of the global total.Among the elderly over the age of 60, the prevalence of cataracts is more than 46%, and this number is still rising. Surgical treatment is the most effective treatment of senile cataract Means, but for Chinese patients, the proportion of patients receiving Fuming surgery is lower, compared with the developed countries there is a big gap.

According to the National Health and Family Planning Commission Office issued "13th National Eye health (2016-2020) ", the number of cataract operations (CSR) per million population in China has surpassed 1,500 cases / million in 2015, up 56% from the end of the 11th five-year plan period. However, with more than 9,000 CRS cases in developed countries, / Million population / year there is still a big gap between this aspect stems from the lack of awareness of the standardization of treatment, on the other hand from patients often face the high cost of imported surgical products to the burden.

It is understood that the intraocular lens is a special lens made of synthetic materials, surgery is the most important material for cataract surgery by removing turbid cataract patients, the intraocular lens implantation of the lens to replace the original, can make cataracts The patient resumes sight.

With the increasing number of cataract and surgery, the demand for intraocular lenses used in surgery will also be greater.About 2.3 million cataract surgeries are performed annually in our country, and 30% of them are still using hard-worn artificial Crystals and clinical use of soft IOL accounts for more than 90% of the total, and the gap between domestic and imported markets is huge. It is estimated that the annual cataract surgery in China will reach 4 million by 2020, and the demand for clinical treatment of eye diseases in China is huge.

According to statistics, in 2016, the scale of China's cataract industry is close to 15 billion yuan, while the majority of ophthalmic surgical supplies currently rely on imports, the local ophthalmic industry is still lagging behind developed countries, and the cataract surgery rate in China is still low. The introduction of new technologies and the development of the entire industry, domestic quality and reasonable price of medical supplies research and innovation has become a major era of efforts.

The pathogenesis of cataract mainly includes senile cataract, diabetic cataract, radiation and trauma caused by cataract.Currently, there are about a dozen domestic cataract drugs.

According to the statistics of the sample hospitals, the sales of cataract drugs were 14.48 million yuan in 2016. The main varieties are: pirnixin (sample hospital sales of 7.31 million yuan, the same below), barrier eye (351 million yuan), ammonia (1720000 yuan), benzyl Daisy (1.25 million yuan), glutathione (530000 yuan), and the other law and forest compound and thyroxine / liothyronine etc .. In recent years, cataract The competition in the drug market is getting fiercer and fiercer, but the overall size of the sample hospital is not large, which is mainly related to the less number of ophthalmology hospitals in the sample.

In terms of dosage form, the sales of cataract eye drops in sample hospitals in 2016 were RMB 9.94 million, accounting for 68.9%; the sales volume of capsules was 2.36 million yuan, accounting for 16.3%; the sales of tablets were 1.15 million yuan, accounting for 7.9% ; Injections sales of 1.04 million yuan, accounting for 7.2% of which eye drops occupy an absolute advantage.As cataract drug eye drops mostly belong to OTC Drugs, the market is mainly concentrated in the retail terminal, therefore, the overall size of the sample hospital smaller.

In 2016, the sample hospital involved in the production of cataract drugs enterprise There are nearly 20, the top 5 companies total sales of 12.4 million yuan, accounting for 85.7% of the overall market, the market is more concentrated.The top five companies are: towering (sample hospital Sales of 6270000 yuan, accounting for 45.7%, the same below), Hunan Tianjitangtang pharmaceutical (2220000 yuan, accounting for 15.3%), Zhejiang Guoguang medicine (1.7 million yuan, accounting for 11.7%), Guangzhou, a medicine 115 million yuan, accounting for 7.9%), Changchun PricewaterhouseCoopers (720,000 yuan, accounting for 5.%).